BENDAMUSTINE HYDROCHLORIDE FOR INJECTION POWDER FOR SOLUTION

Land: Kanada

Språk: engelska

Källa: Health Canada

Aktiva substanser:

BENDAMUSTINE HYDROCHLORIDE

Tillgänglig från:

HIKMA CANADA LIMITED

ATC-kod:

L01AA09

INN (International namn):

BENDAMUSTINE

Dos:

25MG

Läkemedelsform:

POWDER FOR SOLUTION

Sammansättning:

BENDAMUSTINE HYDROCHLORIDE 25MG

Administreringssätt:

INTRAVENOUS

Enheter i paketet:

100

Receptbelagda typ:

Prescription

Produktsammanfattning:

Active ingredient group (AIG) number: 0153268001; AHFS:

Bemyndigande status:

APPROVED

Tillstånd datum:

2022-05-02

Produktens egenskaper

_Product Monograph _
_Bendamustine Hydrochloride for Injection _
_ _
_ _
_Page 1 of 44 _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
BENDAMUSTINE HYDROCHLORIDE FOR INJECTION
(bendamustine hydrochloride for injection)
Lyophilized Powder for Injection, for intravenous infusion
25 mg / vial and 100 mg / vial
USP
Antineoplastic agent
Hikma Canada Limited
5995 Avebury Road,
Suite 804, Mississauga,
Ontario L5R 3P9
Date of Initial Authorization:
April 28, 2022
Submission Control Number: 238015
_Product Monograph _
_Bendamustine Hydrochloride for Injection _
_ _
_ _
_Page 2 of 44 _
_ _
RECENT MAJOR LABEL CHANGES
N/A
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGE…………………………………………………………………………………………..2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
........................................................................................................
4
1.2
Geriatrics.........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
.....................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.................................................. 5
4.3
Recons